clinical trial · NCT06937099
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Eli Lilly and Company·phase3·recruiting·n = 290
Crohn's DiseaseObesity or OverweightMirikizumabMirikizumabTirzepatidePlacebo
brief summary
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
started
Jun 26, 2025
primary completion
May 1, 2028
completion
May 1, 2028
last updated
Jun 3, 2026
official title
A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol